| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 408.4 | 560.6 | 99.7 |
| Other income | 3.1 | 4.8 | 0.8 |
| Total income | 411.5 | 565.4 | 100.5 |
| Profit before exceptional items & tax | 75.9 | 131.8 | -30.4 |
| Profit before tax | 75.9 | 131.8 | -31.3 |
| Net profit | 52.7 | 95.8 | -23.9 |
| Operating margin | 18.4% | 23.3% | -31.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | -45.00% |
|---|---|
| Revenue, year on year | +309.60% |
| Operating profit, year on year | +333.30% |
| Operating profit, quarter on quarter | -42.70% |
NSE results filing, NSE: MOLBIO. Figures extracted from the filing.
Molbio Diagnostics Ltd: key numbers
- Share price
- ₹1,246.00
- Market cap
- ₹14,359 Cr
- Revenue (annual)
- ₹1,446 Cr
- Net profit (annual)
- ₹166.6 Cr
- Promoter holding
- 41.29%
- FII holding
- 1.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Molbio Diagnostics Ltd
All →Molbio Diagnostics Other Announcement
Molbio Diagnostics Limited re-appointed M/s. K.S. Kamalakara & Co as Cost Auditors for a 12-month term. The decision was finalized during a board meeting on September 25, 2026.
- Execution
- 12 months
Molbio Diagnostics Board Meeting Outcome
Molbio Diagnostics Limited has re-appointed M/s K. S. Kamalakara & Co as its Cost Auditor for the financial year 2026-27. The Board approved the appointment today.
- Execution
- Financial Year 2026-27
Molbio Diagnostics Capital Structure Change
India Business Excellence Fund III sold 30,00,000 shares (2.60% stake) of Molbio Diagnostics Limited. The transaction was executed via open market on September 23, 2026.
Molbio Diagnostics Earnings Call Transcript: Key Takeaways
Molbio reported Q1 FY27 revenue of ₹408 Cr with a 25% EBITDA margin. Strategy focuses on expanding Truenat's global footprint and integrating digital pathology via OptraScan.
- Call
- Guides 25% growth
Molbio Diagnostics Other Announcement
Molbio Diagnostics informed exchanges that its CIN changed from U33125GA2000PLC002909 to L33125GA2000PLC002909 post-listing. The MCA status was updated from Unlisted to Listed.
Molbio Diagnostics Investor Presentation: Key Takeaways
Molbio Diagnostics listed on Aug 17, 2026. Q1 FY27 saw Total Income of ₹411.5 Cr and EBITDA of ₹103.7 Cr, transitioning from a loss in Q1 FY26 driven by higher test-kit consumption.